title: Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.
abstract: Antisense oligonucleotide (ASO) drugs are an emerging class of therapeutics that have recently demonstrated progress and promise to treat diseases of the central nervous system (CNS). ASOs for a variety of targets and mechanisms are currently being investigated in clinical trials and pre-clinically for a number of CNS diseases. This review examines the available data regarding central ASO delivery, distribution, pharmacokinetics, pharmacodynamics and therapeutic opportunities. This article is part of the Special Issue entitled "Beyond small molecules for neurological disorders".
authors.affiliation: Otonomy, 6275 Nancy Ridge Drive, San Diego, 92121, CA, USA. Electronic address: kbishop@otonomy.com.
authors.forename: Kathie M
authors.initials: KM
authors.lastname: Bishop
mesh_terms: D000818:Animals; D002491:Central Nervous System Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D016503:Drug Delivery Systems; D006801:Humans; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D002491:Central Nervous System Agents; D020319:Oligodeoxyribonucleotides, Antisense
keywords: Antisense oligonucleotides; CNS diseases; Drug development